In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. More participants will be enrolled with the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be provided as "insert-on" therapy. In Phase C, contributors https://abbv-744-brd4-inhibition72368.angelinsblog.com/31301810/little-known-facts-about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers